Skip to content
15% off your first order15% off your first order

KLOW 80 mg pre-filled pen

TB-500 + BPC-157 + GHK-Cu + KPV

Four-peptide repair blend

Four repair and renewal compounds in one pen.

$239.95CAD
Format. Vial or pen?
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Pre-filled, with 4 pen needles in the box. Just add wipes.

Compare. Side by side, from the research.

About KLOW

KLOW combines four compounds studied across repair and renewal: TB-500, BPC-157, GHK-Cu, and KPV. The inclusion of GHK-Cu gives it a foot in both the Foundation and Longevity families.

How it works

Layered Mechanisms
Four compounds studied for distinct but adjacent pathways across tissue repair, remodeling, and inflammatory tone.
Crossover Profile
The GHK-Cu component is studied for skin and connective-tissue renewal, which is why this sits across two families.
Read the full research

What you need

  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Disposable pre-filled pen · 4 pen needles included
Strength
80 mg per pre-filled pen
Storage
Refrigerate, away from light.
Route in research
Subcutaneous
SKU
KLOW80DSP
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Preclinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

PreclinicalThe four-compound KLOW blend has not been evaluated as a combination, and research on its components comes mainly from animal and cell studies, with only small, limited human reports for BPC-157.

What research examines

  • Musculoskeletal soft tissue healing in animal models (BPC-157)
  • Wound healing and epithelial repair (BPC-157)
  • Skin and connective-tissue renewal (GHK-Cu)
  • Gene expression linked to regenerative and protective actions (GHK-Cu)
  • Cytoskeletal regulation in tissue repair (TB-500)
  • Inflammatory balance (KPV)

Reported in studies

  • Human safety data for the combined blend are limited
  • Adverse events for the four-compound combination have not been characterized in published studies
  • Recent narrative review literature has raised open questions about the risk-benefit profile of BPC-157
  • Human evidence for BPC-157 is limited to small reports, so safety conclusions remain preliminary
Read the full research page· 5 cited studies

Published research protocols

4 mg, daily, am fasted

Research protocols have used 2–4 mg per administration, once daily (morning, fasted), in 8-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

CoreX AI

Ask about KLOW

Plain answers, from the basics to the studies.

Research information, not medical advice.

Often researched with KLOW

FAQ

Questions, answered

  • KLOW is a research blend that combines four compounds in one vial: TB-500, BPC-157, GHK-Cu, and KPV. Each component has been studied in its own right across tissue repair, remodeling, and inflammatory signaling. Because GHK-Cu is also studied for skin and connective-tissue renewal, the blend is grouped in both the Foundation and Longevity families. The combination itself has not been studied as a single formulation in published research.

  • Each compound is studied for a different step in repair. TB-500 is associated with cytoskeletal regulation, BPC-157 with angiogenic and epithelial signaling, GHK-Cu with copper-dependent tissue remodeling, and KPV with inflammatory balance. The rationale for the blend is that these distinct but adjacent pathways may be relevant to tissue repair together. Whether combining them produces additive or different effects has not been established experimentally.

  • BPC-157 has been reviewed for musculoskeletal soft tissue healing, wound healing, and emerging orthopaedic sports medicine applications, largely based on animal work. GHK-Cu has been studied for regenerative and protective actions, including gene expression data, anti-aging research, and topical anti-wrinkle applications. TB-500 and KPV are studied for cytoskeletal regulation and inflammatory balance, respectively. Published research on the four-compound blend as a combination is not available.

  • Human safety data for the KLOW blend are limited, and adverse events for the combined formulation have not been characterized in published studies. Evidence for BPC-157 in humans consists of small reports, and recent narrative review literature has questioned whether its regenerative potential is balanced by adequately understood risks. Safety conclusions for each component, and especially for their combination, should be regarded as preliminary.

  • Research protocols have used 2–4 mg per administration, once daily in the morning in a fasted state, in 8-week blocks followed by 4 weeks off, delivered by the subcutaneous route. These figures describe what protocols have used rather than an established or validated dose, as the blend has not been evaluated in controlled studies. Each CoreX order ships with a protocol guide for laboratory reference.